Prevalence and incidence of bronchiectasis in Catalonia, Spain: A population-based study

Monteagudo, Mónica; Rodríguez-Blanco, Teresa; Barrecheguren, Miriam; Simonet, Pere; Miravitlles, Marc

doi:10.1016/j.rmed.2016.10.014

Cited by 69 publications

(44 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A large population based study in Catalonia (north-eastern Spain) similarly found high prevalence (36.2 cases per 10,000) and incidence rates (4.81 cases per 10,000). In contrast to other global datasets, the prevalence and incidence of bronchiectasis in this study was highest in older males [48]. A larger multicentre study in Spain however showed contrasting results with higher prevalence in females and elevated rates of post-infectious disease [30].…”

Section: Bronchiectasis In Europecontrasting

confidence: 99%

Geographic variation in the aetiology, epidemiology and microbiology of bronchiectasis

et al. 2018

View full text Add to dashboard Cite

Bronchiectasis is a disease associated with chronic progressive and irreversible dilatation of the bronchi and is characterised by chronic infection and associated inflammation. The prevalence of bronchiectasis is age-related and there is some geographical variation in incidence, prevalence and clinical features. Most bronchiectasis is reported to be idiopathic however post-infectious aetiologies dominate across Asia especially secondary to tuberculosis. Most focus to date has been on the study of airway bacteria, both as colonisers and causes of exacerbations. Modern molecular technologies including next generation sequencing (NGS) have become invaluable tools to identify microorganisms directly from sputum and which are difficult to culture using traditional agar based methods. These have provided important insight into our understanding of emerging pathogens in the airways of people with bronchiectasis and the geographical differences that occur. The contribution of the lung microbiome, its ethnic variation, and subsequent roles in disease progression and response to therapy across geographic regions warrant further investigation. This review summarises the known geographical differences in the aetiology, epidemiology and microbiology of bronchiectasis. Further, we highlight the opportunities offered by emerging molecular technologies such as -omics to further dissect out important ethnic differences in the prognosis and management of bronchiectasis.

show abstract

Section: Bronchiectasis In Europecontrasting

confidence: 99%

Geographic variation in the aetiology, epidemiology and microbiology of bronchiectasis

et al. 2018

View full text Add to dashboard Cite

show abstract

“…In Spain up to 10% of the adult population has COPD10 and 1.5% of men older than 65 years have bronchiectasis;11 therefore, they may both coexist. Although the diagnosis of COPD is based on physiology and that of bronchiectasis on morphology, both diseases may result in similar lung function abnormalities and non-specific respiratory symptoms.…”

Section: Copd and Bronchiectasis: Under-and Misdiagnosismentioning

confidence: 99%

Bronchiectasis in COPD patients: more than a comorbidity?

Martínez-García

Miravitlles

2017

COPD

Self Cite

121

View full text Add to dashboard Cite

Computed tomography scan images have been used to identify different radiological COPD phenotypes based on the presence and severity of emphysema, bronchial wall thickening, and bronchiectasis. Bronchiectasis is defined as an abnormal dilation of the bronchi, usually as a result of chronic airway inflammation and/or infection. The prevalence of bronchiectasis in patients with COPD is high, especially in advanced stages. The identification of bronchiectasis in COPD has been defined as a different clinical COPD phenotype with greater symptomatic severity, more frequent chronic bronchial infection and exacerbations, and poor prognosis. A causal association has not yet been proven, but it is biologically plausible that COPD, and particularly the infective and exacerbator COPD phenotypes, could be the cause of bronchiectasis without any other known etiology, beyond any mere association or comorbidity. The study of the relationship between COPD and bronchiectasis could have important clinical implications, since both diseases have different and complementary therapeutic approaches. Longitudinal studies are needed to investigate the development of bronchiectasis in COPD, and clinical trials with treatments aimed at reducing bacterial loads should be conducted to investigate their impact on the reduction of exacerbations and improvements in the long-term evolution of the disease.

show abstract

“…There is growing evidence that incidence and prevalence of bronchiectasis and associated hospitalisations are increasing. The highest bronchiectasis prevalence rates have been reported in the United Kingdom (2013: 566.1 per 100,000 inhabitants in men and 485.5 per 100,000 inhabitants in women) and Catalonia (2012: 362 per 100,000 inhabitants) 20,26 . In 2013, Ringshausen et al 27 based on International Statistical Classification of Diseases and Related Health Problems, 10th revision (ICD-10) diagnosis codes found a much lower prevalence in Germany of 67 per 100,000 inhabitants.…”

Section: Barcelona Respiratory Networkmentioning

confidence: 99%

Bronchiectasis Exacerbations: Clinical Relevance and Management

Mendes¹,

Shoemark²,

Chalmers³

2018

BRN

View full text Add to dashboard Cite

Bronchiectasis is a clinico-radiological syndrome with variable course. Some patients are stable for years and others develop frequent exacerbations, characterised by symptoms such as increased cough and change in sputum and/or systemic features. Bacterial infections are the most frequent recognised trigger, and consequently the majority of these events are treated with systemic antibiotics. As a major cause of morbidity, mortality and healthcare related costs, exacerbations have been used as primary outcomes in clinical trials of new treatments in bronchiectasis. Furthermore, implementing prevention strategies in patients at risk of future exacerbations is a major goal of bronchiectasis management. However, evidence-based knowledge on bronchiectasis exacerbations is limited and there is no specific licensed-treatment. Further studies using the recently developed consensus-based definition are needed to clarify the unanswered questions regarding the pathophysiology, prevention and treatment of bronchiectasis exacerbations. This review summarises the existing evidence and the gaps in our knowledge of bronchiectasis exacerbations. (BRN Rev. 2018;4(3):169-84)

show abstract

Prevalence and incidence of bronchiectasis in Catalonia, Spain: A population-based study

Abstract: The prevalence and incidence of bronchiectasis increases with age. The management of bronchiectasis in primary care was not optimal, and the disease continues to represent an important clinical burden.

Cited by 69 publications

References 26 publications

Geographic variation in the aetiology, epidemiology and microbiology of bronchiectasis

Geographic variation in the aetiology, epidemiology and microbiology of bronchiectasis

Bronchiectasis in COPD patients: more than a comorbidity?

Bronchiectasis Exacerbations: Clinical Relevance and Management

Contact Info

Product

Resources

About